CurrentBlue Cross Blue Shield - MassachusettsPolicy 307

Saturation Biopsy for Prostate Cancer Policy

Defines Blue Cross Blue Shield of Massachusetts coverage position for saturation prostate biopsy (transrectal or transperineal, template-guided) across Commercial and Medicare products, includes authorization requirements and coding information. Provides clinical evidence summary and policy history.

Policy Summary

PayerBlue Cross Blue Shield - Massachusetts

PolicySaturation Biopsy for Prostate Cancer Policy

Policy CodePolicy 307

Change TypeAnnual reviewcoding clarification

Effective DateJan 19, 2011

Next Review Date

Key ActionPrecertification/preauthorization is required for all products if saturation biopsy is performed inpatient.

SourceLink

POLICY UPDATE CHANGES

Annual policy review 9/2025: Policy updated with literature review through 15,2025; policy statement unchanged.

10/2023: Clarified coding information.

Multiple prior annual reviews updated description, summary and references with policy statements unchanged.

1Coverage stance (investigational/not covered)

2Codes listed as investigational

15Years since effective date (approx.)

Coverage Summary & Determination

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

This policy defines the coverage position for saturation prostate biopsy (sampling >20 cores), whether performed transrectally or transperineally (template-guided), and includes authorization and coding information across Commercial and Medicare products. The policy stance is that saturation biopsy of the prostate is investigational / not covered for diagnosis, staging, and management of prostate cancer.

Effective date: 2011-01-19. Last review / most recent annual policy review: 2025-09-15 (policy statement unchanged after literature updates).

Coverage Determination

Saturation biopsy is considered investigational in the diagnosis, staging, and management of prostate cancer.

Policy Statement: Saturation biopsy of the prostate is investigational for diagnosis, staging, and management of prostate cancer
Commercial Managed Care (HMO and POS), Outpatient: This is not a covered service
Commercial PPO and Indemnity, Outpatient: This is not a covered service
Medicare HMO BlueSM, Outpatient: This is not a covered service
Medicare PPO BlueSM, Outpatient: This is not a covered service

ref

title

errors

extra_field_examples_removed

Prior Authorization / Precertification Requirements

Authorization rules for inpatient and outpatient settings

Inpatient Precertification: For services described in this policy, precertification/preauthorization IS REQUIRED for all products if the procedure is performed inpatient
Outpatient Prior Authorization: Outpatient: see product-specific prior authorization requirements; for Commercial Managed Care outpatient the service is not covered

ref

title

errors

Operational Requirements & Billing Impact

Prior Authorization

Inpatient precertification required

Precertification/preauthorization is required for all products if saturation biopsy is performed inpatient.

Documentation Required

Verify member benefits

Refer to the member's contract benefits in effect at the time of service to determine coverage or non-coverage for an individual member.

Billing Rule

Report services with current codes

Providers should report all services using the most up-to-date industry-standard procedure, revenue, and diagnosis codes, including modifiers where applicable.

55706
G0416

Clinical Background & Evidence Summary

Saturation biopsy generally refers to taking more than 20 cores to improve sampling of anterior zones and can be performed transrectally or transperineally; the transperineal approach is often a stereotactic template-guided procedure performed under general anesthesia. By contrast, an extended biopsy strategy commonly uses 12–14 cores and is frequently used for initial biopsy in the office setting.

Saturation biopsy has been proposed for multiple clinical uses including initial or repeat diagnosis, improved staging, and as part of active surveillance to better evaluate tumor grade, but the policy considers the approach investigational for these indications.

Definitions

Evidence summary

Policy Revisions & Updates

9/2025revisedLatest